July 15, 2020
SONGDO, South Korea, July 15, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics held a signing ceremony today for a contract to develop and manufacture five candidate molecules, expanding upon the two companies' existing CDO partnership first established in...
Source URL: https://www.prnewswire.com:443/news-releases/samsung-biologics-and-immuneoncia-sign-multi-product-development-and-manufacturing-agreement-301093634.html
|
